GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
Metrics: PDF 597 views | HTML 1241 views | ?
Jian Zhang1,*, Ying Wu1,*, Xichun Hu1, Biyun Wang1, Leiping Wang1, Sheng Zhang1, Jun Cao1 and Zhonghua Wang1
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
*These authors have contributed equally to this work
Zhonghua Wang, email: email@example.com
Keywords: GSTT1; GSTP1; GSTM1; polymorphism; metastatic breast cancer
Received: December 12, 2016 Accepted: August 29, 2017 Published: November 14, 2017
Purpose: The polymorphisms in genes including GSTM1, GSTP1 and GSTT1 have been found to predict development and therapeutic efficacy in various malignancies. Breast cancer is one of most common cancers among women. In this study, we evaluated the prognostic value of three functional polymorphisms of GSTs in patients with previously untreated metastatic breast cancer (MBC).
Patients and Methods: The genotype of GSTT1, GSTP1, and GSTM1 in 170 patients with previously untreated MBC from one single center were assessed via PCR-based RFLP methods. The prognostic of polymorphisms on overall survival (OS) was examined using the Kaplan-Meier estimates and Cox proportional hazard ratio (HR) regression analyses.
Results: The null genotypes of GSTT1 and GSTM1 were significantly correlated to poor OS compared with the present genotypes, respectively. After adjusting for clinic-pathologic factors, GSTT1 and GSTM1 genetic variants were still significantly associated with OS (HR, 1.92; 95% CI, 1.26-2.91 and HR, 1.53; 95% CI, 1.05-2.23). GSTT1 and GSTM1 were independent survival predictors and GSTP1 was not associated with overall survival of previous untreated MBC.
Conclusion: This exploratory analysis suggests that in addition to clinic-pathologic factors, the genetic variants in GSTT1 and GSTM1 might be predictive of survival outcome in patients with previously untreated MBC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.